{"id":"NCT02278120","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","officialTitle":"A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11-20","primaryCompletion":"2017-08-21","completion":"2023-04-20","firstPosted":"2014-10-29","resultsPosted":"2019-02-26","lastUpdate":"2024-03-12"},"enrollment":672,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Advanced Metastatic Breast Cancer"],"interventions":[{"type":"DRUG","name":"Ribociclib","otherNames":["LEE011"]},{"type":"DRUG","name":"Tamoxifen","otherNames":[]},{"type":"DRUG","name":"Letrozole","otherNames":[]},{"type":"DRUG","name":"Anastrozole","otherNames":[]},{"type":"DRUG","name":"Goserelin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ribociclib + NSAI/tamoxifen + goserelin","type":"EXPERIMENTAL"},{"label":"Placebo + NSAI/tamoxifen + goserelin","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to determine whether treatment with tamoxifen or a non-steroidal aromatase inhibitors (NSAI) + goserelin + LEE011 prolonged progression-free survival (PFS) compared to treatment with tamoxifen or a NSAI + goserelin + placebo in premenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.","primaryOutcome":{"measure":"Progression Free Survival (PFS) by Investigator Assessment","timeFrame":"From randomization to first documented progression or death, assessed up to approximately 29 months","effectByArm":[{"arm":"Ribociclib + NSAI/Tamoxifen + Goserelin","deltaMin":23.8,"sd":null},{"arm":"Placebo + NSAI/Tamoxifen+ Goserelin","deltaMin":13,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0000001"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":9},"locations":{"siteCount":183,"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","Colombia","France","Germany","Greece","Hong Kong","Hungary","India","Italy","Lebanon","Malaysia","Mexico","Poland","Portugal","Russia","Saudi Arabia","Singapore","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (TÃ¼rkiye)","United Arab Emirates"]},"refs":{"pmids":["39826197","37673211","36800111","34965945","34504990","34158598","33769862","31305131","31166679","29804902"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":81,"n":335},"commonTop":["Arthralgia","Hot flush","Neutropenia","Nausea","Headache"]}}